CD3zeta expression and T cell proliferation are inhibited by TGF-beta1 and IL-10 in cervical cancer patients.
BACKGROUND
Cervical cancer development from a squamous intraepithelial lesion is thought to be favored by an impaired T cell immunity. We evaluated parameters of T cell alterations such as proliferation, cytokine, and CD3zeta expression in peripheral blood and tumor-infiltrating T lymphocytes from women with squamous intraepithelial lesions (SIL) or cervical cancer (CC).


CONCLUSIONS
T cell proliferation and cytokine messenger RNA (mRNA) expression were similar in women with SIL and healthy donors, whereas low T cell proliferation and lower mRNA expression of IL-2, IL-10 and IFN-gamma were observed in women with CC. Moreover, infiltrating cells showed marginal responses. We also found that CD3zeta mRNA expression, whose protein is required for T cell activation, correlated with a decreased proliferation in advanced stages of the disease.


CONCLUSIONS
Experiments with T cells from healthy donors in the presence TGF-beta1 or IL-10 suggest that these cytokines have a relevant role in T cell responses during CC progression.
Díaz-Benítez
Cinthya E
CE
División de Infecciones Crónicas y Cáncer, Instituto Nacional de Salud Pública de México, Sta María Ahuacatitlán, 62508 Cuernavaca, Morelos, Mexico.
Navarro-Fuentes
Karla R
KR
Flores-Sosa
Jacqueline A
JA
Juárez-Díaz
Janet
J
Uribe-Salas
Felipe J
FJ
Román-Basaure
Edgar
E
González-Mena
Ludwig E
LE
Alonso de Ruíz
Patricia
P
López-Estrada
Guillermina
G
Lagunas-Martínez
Alfredo
A
Bermúdez-Morales
Victor H
VH
Alcocer-González
Juan M
JM
Martínez-Barnetche
Jesús
J
Hernández-Pando
Rogelio
R
Rosenstein
Yvonne
Y
Moreno
José
J
Madrid-Marina
Vicente
V
D000328:Adult; D000368:Aged; D017252:CD3 Complex / Q000096:biosynthesis* / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D017077:Culture Media, Conditioned / Q000494:pharmacology; D005260:Female; D006367:HeLa Cells; D006801:Humans; D007371:Interferon-gamma / Q000276:immunology / Q000378:metabolism; D016753:Interleukin-10 / Q000276:immunology* / Q000494:pharmacology; D007376:Interleukin-2 / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating / Q000187:drug effects / Q000276:immunology*; D008875:Middle Aged; D010835:Phytohemagglutinins / Q000494:pharmacology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D053773:Transforming Growth Factor beta1 / Q000276:immunology* / Q000494:pharmacology; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000473:pathology; D002578:Uterine Cervical Dysplasia / Q000276:immunology* / Q000473:pathology
D017252:CD3 Complex; C121704:CD3 antigen, zeta chain; D017077:Culture Media, Conditioned; C508609:IL10 protein, human; C508594:IL2 protein, human; D007376:Interleukin-2; D010835:Phytohemagglutinins; D053773:Transforming Growth Factor beta1; D016753:Interleukin-10; D007371:Interferon-gamma